SCHEMBL809767

SCHEMBL809767

OCc1ccccc1-c1ccc(CBr)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.44
ALDH1A1 P00352 1/20 0.44
TSHR P16473 1/20 0.44
PDCD1 Q15116 1/20 0.44
CD274 Q9NZQ7 1/20 0.44
LTB4R2 Q9NPC1 1/20 0.43
PDK2 Q15119 1/20 0.43
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
DPP4 P27487 1/20 0.41
KMT2A Q03164 1/20 0.39
PTGER1 P34995 1/20 0.39
PTGER4 P35408 1/20 0.39
PTGER3 P43115 1/20 0.39
PTGER2 P43116 1/20 0.39
FFAR1 O14842 6/20 0.38
FFAR4 Q5NUL3 6/20 0.38
APOBEC3G Q9HC16 1/20 0.38
ADORA2A P29274 2/20 0.35
HTR2B P41595 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1309773 0.88 ALDH1A1 (0.48) TRPA1ALDH1A1TSHRPDCD1CD274
SCHEMBL6448256 0.85 TSHR (0.50) TSHRPDCD1CD274LTB4R2PDK2
SCHEMBL10892045 0.83 ALDH1A1 (0.57) TRPA1ALDH1A1TSHRCES2CES1
SCHEMBL809887 0.82 DPP4 (0.64) TRPA1ALDH1A1TSHRCES2CES1
SCHEMBL175541 0.80 PTGS1 (0.50) TSHRCES2CES1KMT2APTGER1
SCHEMBL6499360 0.80 DPP4 (0.55) PDCD1CD274LTB4R2PDK2DPP4
SCHEMBL3859896 0.79 PDCD1 (0.47) ALDH1A1TSHRPDCD1CD274LTB4R2
SCHEMBL7951583 0.79 PDCD1 (0.61) ALDH1A1PDCD1CD274LTB4R2PDK2
SCHEMBL10535771 0.79 PDCD1 (0.45) TRPA1ALDH1A1TSHRPDCD1CD274
SCHEMBL9023806 0.79 ALDH1A1 (0.59) TRPA1ALDH1A1TSHRCES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968727-B2 Synthesis of 4-bromomethyl-2′-formylbiphenyl and 4-bromomethyl-2′-hydroxymethylbiphenyl and its use in preparation of angiotensin II antagonists LEK PHARMACEUTICALS, D.D. (SI) 2011-06-28 US claimed
US-20090318521-A1 Synthesis of 4-Bromomethyl-2'-Formylbiphenyl and 4-Bromomethyl-2'-Hydroxymethylbiphenyl and Its Use in Preparation of Giotensin II Antagonists LEK PHARMACEUTICALS D.D. (SI) 2009-12-24 US claimed
EP-1871764-A1 A SYNTHESIS OF 4-BROMOMETHYL-2'-FORMYLBIPHENYL AND 4-BROMOMETHYL-2'- HYDROXYMETHYLBIPHENYL AND ITS USE IN PREPARATION OF ANGIOTENSIN II ANTAGONISTS LEK Pharmaceuticals D.D. (SI) 2008-01-02 EP claimed
WO-2006103068-A1 A SYNTHESIS OF 4-BROMOMETHYL-2'-FORMYLBIPHENYL AND 4-BROMOMETHYL-2'- HYDROXYMETHYLBIPHENYL AND ITS USE IN PREPARATION OF ANGIOTENSIN II ANTAGONISTS LEK PHARMACEUTICALS D.D. (SI) 2006-10-05 WO claimed
US-7968727-B2 Synthesis of 4-bromomethyl-2′-formylbiphenyl and 4-bromomethyl-2′-hydroxymethylbiphenyl and its use in preparation of angiotensin II antagonists LEK PHARMACEUTICALS, D.D. (SI) 2011-06-28 US disclosed
US-7968727-B2 Synthesis of 4-bromomethyl-2′-formylbiphenyl and 4-bromomethyl-2′-hydroxymethylbiphenyl and its use in preparation of angiotensin II antagonists LEK PHARMACEUTICALS, D.D. (SI) 2011-06-28 US disclosed
US-7968727-B2 Synthesis of 4-bromomethyl-2′-formylbiphenyl and 4-bromomethyl-2′-hydroxymethylbiphenyl and its use in preparation of angiotensin II antagonists LEK PHARMACEUTICALS, D.D. (SI) 2011-06-28 US disclosed
US-7968727-B2 Synthesis of 4-bromomethyl-2′-formylbiphenyl and 4-bromomethyl-2′-hydroxymethylbiphenyl and its use in preparation of angiotensin II antagonists LEK PHARMACEUTICALS, D.D. (SI) 2011-06-28 US disclosed
US-7968727-B2 Synthesis of 4-bromomethyl-2′-formylbiphenyl and 4-bromomethyl-2′-hydroxymethylbiphenyl and its use in preparation of angiotensin II antagonists LEK PHARMACEUTICALS, D.D. (SI) 2011-06-28 US disclosed
US-20090318521-A1 Synthesis of 4-Bromomethyl-2'-Formylbiphenyl and 4-Bromomethyl-2'-Hydroxymethylbiphenyl and Its Use in Preparation of Giotensin II Antagonists LEK PHARMACEUTICALS D.D. (SI) 2009-12-24 US disclosed
US-20090318521-A1 Synthesis of 4-Bromomethyl-2'-Formylbiphenyl and 4-Bromomethyl-2'-Hydroxymethylbiphenyl and Its Use in Preparation of Giotensin II Antagonists LEK PHARMACEUTICALS D.D. (SI) 2009-12-24 US disclosed
US-20090318521-A1 Synthesis of 4-Bromomethyl-2'-Formylbiphenyl and 4-Bromomethyl-2'-Hydroxymethylbiphenyl and Its Use in Preparation of Giotensin II Antagonists LEK PHARMACEUTICALS D.D. (SI) 2009-12-24 US disclosed
US-20090318521-A1 Synthesis of 4-Bromomethyl-2'-Formylbiphenyl and 4-Bromomethyl-2'-Hydroxymethylbiphenyl and Its Use in Preparation of Giotensin II Antagonists LEK PHARMACEUTICALS D.D. (SI) 2009-12-24 US disclosed
US-20090318521-A1 Synthesis of 4-Bromomethyl-2'-Formylbiphenyl and 4-Bromomethyl-2'-Hydroxymethylbiphenyl and Its Use in Preparation of Giotensin II Antagonists LEK PHARMACEUTICALS D.D. (SI) 2009-12-24 US disclosed
EP-1871764-A1 A SYNTHESIS OF 4-BROMOMETHYL-2'-FORMYLBIPHENYL AND 4-BROMOMETHYL-2'- HYDROXYMETHYLBIPHENYL AND ITS USE IN PREPARATION OF ANGIOTENSIN II ANTAGONISTS LEK Pharmaceuticals D.D. (SI) 2008-01-02 EP disclosed
EP-1871764-A1 A SYNTHESIS OF 4-BROMOMETHYL-2'-FORMYLBIPHENYL AND 4-BROMOMETHYL-2'- HYDROXYMETHYLBIPHENYL AND ITS USE IN PREPARATION OF ANGIOTENSIN II ANTAGONISTS LEK Pharmaceuticals D.D. (SI) 2008-01-02 EP disclosed
WO-2006103068-A1 A SYNTHESIS OF 4-BROMOMETHYL-2'-FORMYLBIPHENYL AND 4-BROMOMETHYL-2'- HYDROXYMETHYLBIPHENYL AND ITS USE IN PREPARATION OF ANGIOTENSIN II ANTAGONISTS LEK PHARMACEUTICALS D.D. (SI) 2006-10-05 WO disclosed
WO-2006103068-A1 A SYNTHESIS OF 4-BROMOMETHYL-2'-FORMYLBIPHENYL AND 4-BROMOMETHYL-2'- HYDROXYMETHYLBIPHENYL AND ITS USE IN PREPARATION OF ANGIOTENSIN II ANTAGONISTS LEK PHARMACEUTICALS D.D. (SI) 2006-10-05 WO disclosed
WO-2006103068-A1 A SYNTHESIS OF 4-BROMOMETHYL-2'-FORMYLBIPHENYL AND 4-BROMOMETHYL-2'- HYDROXYMETHYLBIPHENYL AND ITS USE IN PREPARATION OF ANGIOTENSIN II ANTAGONISTS LEK PHARMACEUTICALS D.D. (SI) 2006-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318521-A1 Synthesis of 4-Bromomethyl-2'-Formylbiphenyl and 4-Bromomethyl-2'-Hydroxymethylbiphenyl and Its Use in Preparation of Giotensin II Antagonists GRK4, GRK2, GRK5 TRPA1 1634/4885ALDH1A1 3706/4885TSHR 3662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.